News

First patient has been recruited and received his first OT-82 treatment!

July 17th, 2019|

Oncotartis, Inc has received a green light from FDA for its IND application. The Company will start engaging clinical sites immediately. It plans to use 5-10 clinical sites to conduct the trial.

February 27th, 2019|

OncoTartis, Inc has hired a global, full-service contract research organization (CRO), Clinipace, to conduct a Phase 1/2a trial of its drug candidate OT-82 acting against hematological cancers.

December 3rd, 2018|

OncoTartis, Inc. has engaged Dr. Eric Rowinsky to serve an acting Medical Director.

OncoTartis, Inc. has engaged Dr. Eric Rowinsky to serve an acting Medical Director for the upcoming clinical trial of its drug candidate OT-82, a small molecule with anti-leukemia and anti-lymphoma activities. Dr. Rowinsky has more than 25 years of experience managing clinical trials and developing drugs in oncology, including leading the Food and Drug Administration, or FDA, approval of Erbitux® for head and neck and colorectal cancers and advancing eight other biological therapeutics through clinical development while at ImClone. He completed a medical oncology fellowship at The Johns Hopkins Hospital. Dr. Rowinsky was an Associate Professor of Oncology at [...]

March 14th, 2018|

OncoTartis has concluded a $6 million financing round to support the Phase 1 clinical trial of the lead drug candidate OT-82.

OncoTartis Closes $6M Financing Round. BUFFALO, N.Y., Dec. 11, 2017 /PRNewswire/ -- OncoTartis, Inc., a biotechnology company developing a novel category of anti-cancer drugs, has concluded a $6 million financing round to support the Phase 1 clinical trial of its lead drug candidate, OT-82.  Participants in the round included Norma Investments, representing businessman Roman Abramovich, and Pharmstandard International S.A., a venture arm of the largest Russian pharmaceutical company, based in Luxembourg. OT-82 has been isolated for its selective toxicity for a broad range of hematological malignancies. The drug candidate, a Nicotinamide phosphoribosyltransferase (NAMPT) inhibitor, has demonstrated high efficacy in a variety [...]

December 11th, 2017|

OncoTartis, Inc had a successful pre-IND meeting with FDA. FDA answered a number of Company’s questions and gave the Company a valuable advice regarding optimal patient population for clinical trial.

August 31st, 2017|

OT-82 shows impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients

The Preclinical Testing Consortium (PPTC) is a US National Cancer Institute-funded initiative aimed at prioritizing effective drugs for clinical evaluation in pediatric cancers. OT-82 was selected for testing into this program. Results obtained with OT-82 showed impressive effectiveness in systemic patient-derived xenografts from pediatric resistant ALL patients. In addition, OT-82 demonstrated synergy with AraC in combination therapy. Consequently NAMPT inhibition by OT-82 is an attractive strategy for treating leukemia, and these data support further evaluation of this drug in the treatment of high-risk pediatric ALL.

June 2nd, 2017|

OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies

OncoTartis have successfully completed preclinical GLP Toxicology, Pharmacokinetics and Safety studies demonstrating wide therapeutic window of OT-82. In the course of the studies, no ophthalmic toxicity in monkeys and mice was found. The drug did not show any cardiac toxicity in monkey either. Based on the results of pre-clinical studies as well as GLP studies, a dose range for Phase 1 clinical trials was calculated. This trial will open in the beginning of 2018 and first signs of efficacy are projected to be seen already in the first cohorts.

March 10th, 2017|

September 28, 2016: In-life phase of GLP Toxicology studies is completed.

September 28th, 2016|

Pharmatek, Inc., a San Diego based contract development & manufacturing company, started the development of OT-82 dosage form for human clinical studies.

August 1st, 2016|